• AZD1480: Practical JAK2 Inhibitor Workflows

  2026-08-20

  AZD1480 supports mechanism-first cancer assays that connect JAK2 phosphorylation, STAT3 signaling, apoptosis, and tumor-cell behavior. Its value is especially clear in myeloma models and immune–tumor co-cultures, where pathway blockade can test whether inflammatory signals create tumor-protective resistance.

• Taraxasterol, Necroptosis, and Osteoporosis in BMSCs

  2026-08-19

  A 2025 Phytomedicine study identifies taraxasterol as a regulator of necroptosis and osteogenic–adipogenic imbalance in bone marrow mesenchymal stem cells through the PI3K/AKT/PPARγ axis. By combining an ovariectomized mouse model with patient-derived BMSC experiments and multi-omics and target-validation methods, the work provides a mechanistic framework for connecting cell death, mitochondrial injury, and impaired bone formation.

• CCK-8 Ammonium: From Receptor Biology to Translation

  2026-08-19

  Cholecystokinin octapeptide ammonium is more than a neuropeptide reagent. Its sulfation-dependent activity, CCK1R and CCK2R signaling, and context-sensitive effects create a useful framework for connecting zebrafish behavior with neuronal, immune, and cardiovascular research while keeping translational claims evidence-based.

• SEMA3E, β-Catenin, and Beige Fat Thermogenesis

  2026-08-18

  A 2026 mouse study identifies SEMA3E as a positive regulator of beige adipocyte differentiation and thermogenesis in inguinal white adipose tissue. By combining genetic manipulation, adipose transplantation, RNA sequencing, mitochondrial respiration assays, and pathway rescue experiments, the work connects SEMA3E with oxidative phosphorylation and context-dependent Wnt/β-catenin signaling.

• ALKBH5 Lactylation in Antiviral Innate Immunity

  2026-08-18

  The reference study identifies ALKBH5 lactylation as a previously unrecognized regulatory mechanism that strengthens innate immune responses to HSV-1, KSHV, and mpox virus. Its findings connect ESCO2 and SIRT6 to ALKBH5-dependent m6A demethylation of IFN-β mRNA, providing a mechanistic framework for understanding how posttranslational modification limits DNA-virus replication.

• Fangchinoline, TFEB, and H1N1 Lysosomal Defense

  2026-08-17

  The reference study identifies fangchinoline as a lysosome-targeting antiviral candidate that activates TFEB, restores lysosomal gene expression, and interferes with H1N1 entry. Its combination of Connectivity Map screening, transcriptomic analysis, organelle assays, time-resolved infection experiments, and in vivo validation provides a useful framework for studying host-directed antiviral mechanisms.

• ECL Chemiluminescent Substrate Detection Kit for RCC

  2026-08-17

  Translate LDHA-centered renal cell carcinoma findings into a sensitive, reproducible western blot workflow. The Enhanced ECL detection kit supports low-abundance protein measurement, extended signal capture, and compatibility with film, CCD, and laser imaging systems.

• S-Adenosylhomocysteine: From Ratio to Translation

  2026-08-16

  S-Adenosylhomocysteine is more than a methylation-cycle intermediate: it is a strategic perturbation tool for testing how methylation potential shapes metabolic and neural phenotypes. This article connects SAH biology with radiation-induced neuronal differentiation while defining the evidence boundaries for translational research.

• Necrostatin-1 for Cell-Death Pathway Deconvolution

  2026-08-15

  Necrostatin-1 is a RIP1 kinase inhibitor that helps distinguish necroptosis from ferroptosis in mechanistic cancer research. This article applies Nec-1 to the ALOX5–ferroptosis escape findings in bladder cancer, emphasizing assay interpretation, orthogonal controls, and translational limitations.

• Topotecan and Etoposide in First-Line SCLC

  2026-08-14

  This review evaluates topotecan-based combinations as first-line treatment for small cell lung cancer, emphasizing response signals, toxicity, and the limitations of existing cisplatin–etoposide therapy. Its practical contribution is a clinically focused framework for judging whether topotecan can extend treatment options without assuming that promising phase II activity establishes a new standard.

• CNQX Workflows for AMPA/Kainate Pathway Testing

  2026-08-14

  CNQX enables controlled separation of AMPA and kainate signaling from NMDA-receptor activity in electrophysiology, circuit pharmacology, and neurocardiovascular studies. This guide translates a recent cNTS–PVN study into practical assay designs, concentration planning, and troubleshooting strategies.

• GDC-0068 (RG7440) in Spatial mTORC1 Assays

  2026-08-13

  GDC-0068 (RG7440) provides a practical upstream Akt perturbation for connecting PI3K/Akt/mTOR signaling to proliferation, survival, and mTORC1 outputs. Used alongside compartment-targeted tools, it helps distinguish global Akt dependence from location-specific nuclear or lysosomal mTORC1 functions.

• Triacetin Workflows for Metabolic and Cell Assays

  2026-08-13

  Triacetin, or glyceryl triacetate, is more than a formulation excipient: it is a short-chain triacylglycerol that can support glioblastoma, metabolic, and ocular assay workflows. This practical guide connects dose selection, vehicle controls, digestion studies, and troubleshooting to help researchers use BA1710 without mistaking biological activity for passive solvent behavior.

• Spermine Tetrahydrochloride: A Charge-First Guide

  2026-08-12

  Spermine tetrahydrochloride is more than a polyamine reagent: its charge-dependent behavior connects protoplast protection, protein crystallization, and polyphosphazene assembly. This guide translates the foundational protoplast study into practical assay design while defining appropriate boundaries for neuroscience applications.

• Aztreonam Workflows for Resistant Gram-Negative Research

  2026-08-11

  Build focused antimicrobial, transmission, and translational assays with Aztreonam, a chemically defined monocyclic β-lactam antibiotic for Gram-negative aerobic bacteria. This workflow connects genotype-resolved CREC studies with practical solubility, phenotyping, and troubleshooting decisions without treating research findings as clinical guidance.

3732 records 7/249 page Previous Next First page 上5页 678910 下5页 Last page